Patents Assigned to Mesoblast International Sarl
-
Publication number: 20200281984Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.Type: ApplicationFiled: March 24, 2020Publication date: September 10, 2020Applicant: Mesoblast International SarlInventors: Silviu Itescu, Paul Simmons
-
Patent number: 10729727Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: GrantFiled: November 29, 2018Date of Patent: August 4, 2020Assignee: Mesoblast International SárlInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Publication number: 20200231936Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: December 23, 2019Publication date: July 23, 2020Applicant: Mesoblast International SarlInventors: Samson TOM, Christopher Ton, Alla Danilkovitch
-
Patent number: 10716814Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: GrantFiled: November 30, 2018Date of Patent: July 21, 2020Assignee: Mesoblast International SàrlInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Patent number: 10668101Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: GrantFiled: December 23, 2013Date of Patent: June 2, 2020Assignee: MESOBLAST INTERNATIONAL SÁRLInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Patent number: 10662234Abstract: The present invention features methods for treating or ameliorating tissue damage using intravenous administration of compositions that include stromal cell derived factor-1 (SDF-1) peptides or mutant SDF-1 peptides that have been mutated to make them resistant to protease digestion, but which retain chemoattractant activity. Systemic delivery, and specifically intravenous (“IV”) delivery, of SDF-1 and protease resistant SDF-1 mutants is very effective for the treatment of tissue damage.Type: GrantFiled: June 6, 2012Date of Patent: May 26, 2020Assignee: Mesoblast International SàrlInventors: Anthony Sandrasagra, Weitao Wu
-
Publication number: 20200140822Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.Type: ApplicationFiled: May 4, 2016Publication date: May 7, 2020Applicant: Mesoblast International SàrlInventors: Paul Simmons, Colby Suire, Fiona See
-
Patent number: 10624930Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.Type: GrantFiled: June 1, 2015Date of Patent: April 21, 2020Assignee: MESOBLAST INTERNATIONAL SARLInventors: Silviu Itescu, Paul Simmons
-
Publication number: 20200040303Abstract: The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.Type: ApplicationFiled: October 11, 2019Publication date: February 6, 2020Applicant: Mesoblast International SàrlInventors: Paul Simmons, Colby Suire
-
Patent number: 10550369Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: GrantFiled: April 4, 2018Date of Patent: February 4, 2020Assignee: Mesoblast International SarlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20190345452Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.Type: ApplicationFiled: June 7, 2019Publication date: November 14, 2019Applicant: Mesoblast International SarlInventors: Silviu Itescu, Paul Simmons
-
Patent number: 10456451Abstract: The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity.Type: GrantFiled: February 26, 2016Date of Patent: October 29, 2019Assignee: Mesoblast International SàrlInventors: Vincent Frans Maria Segers, Anthony Sandrasagra, Yan Qiu
-
Patent number: 10400218Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic application.Type: GrantFiled: April 7, 2015Date of Patent: September 3, 2019Assignee: MESOBLAST INTERNATIONAL SARLInventors: Silviu Itescu, Paul Simmons
-
Patent number: 10391127Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: GrantFiled: December 23, 2013Date of Patent: August 27, 2019Assignee: Mesoblast International SárlInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Publication number: 20180291347Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: April 4, 2018Publication date: October 11, 2018Applicant: Mesoblast International SarlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20180142201Abstract: An apparatus for separating cells from microcarriers comprises a chamber having a body and a base. The chamber is configured to receive a mixture comprising cells and microcarriers. The apparatus further comprises a filtration element disposed within the chamber and coupled to the body. The filtration element is configured to filter microcarriers from the mixture. The apparatus further comprises an adjustment mechanism coupled to the chamber. The adjustment mechanism is configured for selective extension and retraction of at least a portion of the body of the chamber to move the filtration element relative to the base of the chamber.Type: ApplicationFiled: May 27, 2016Publication date: May 24, 2018Applicant: Mesoblast International SàrlInventors: Normand Davidzon, Paul Simmons
-
Patent number: 9963678Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: GrantFiled: March 19, 2015Date of Patent: May 8, 2018Assignee: Mesoblast International SàrlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Patent number: 9943547Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.Type: GrantFiled: November 22, 2013Date of Patent: April 17, 2018Assignee: MESOBLAST INTERNATIONAL SÀRLInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Publication number: 20180087032Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.Type: ApplicationFiled: September 1, 2017Publication date: March 29, 2018Applicant: Mesoblast International SárlInventors: Alla DANILKOVITCH, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
-
Publication number: 20180037867Abstract: The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.Type: ApplicationFiled: March 4, 2016Publication date: February 8, 2018Applicant: Mesoblast International SàrlInventors: Paul SIMMONS, Colby SUIRE